Rituximab-resistant splenic memory B ... - stm.sciencemag.org
Patients diagnosed with B cell–mediated autoimmune diseases, such as immune thrombocytopenia (ITP), can benefit from treatment with the B cell–depleting antibody, rituximab. Unfortunately, a large proportion of patients relapse after treatment. To understand why, Crickx et al . evaluated B cell phenotypes and specificity, finding two populations of B cells that may contribute to such relapses.
DA: 12 PA: 74 MOZ Rank: 18